TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Symbio Pharmaceuticals Limited ( (JP:4582) ) just unveiled an update.
SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the fiscal year 2024, with net sales falling by 56.1% and a substantial increase in net loss compared to the previous year. The company continues to face challenges, including a decrease in total assets and cash equivalents, while planning a new subsidiary in the USA, which may impact its future operations and market positioning.
More about Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing oncology and rare disease therapies.
YTD Price Performance: -8.54%
Average Trading Volume: 304,634
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.34B
For a thorough assessment of 4582 stock, go to TipRanks’ Stock Analysis page.